Ensuring integrity in industry-sponsored research: Primum non nocere, revisited

JAMA

Volumn 303, Issue 12, 2010, Pages 1196-1198

  Deangelis, Catherine D ^a   Fontanarosa, Phil B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDITY; WELLBEING; BIOASSAY; ETHICS; INFORMATION PROCESSING; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PEER REVIEW; PHYSICIAN ATTITUDE; PROFESSIONAL STANDARD; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; STANDARD; STATISTICAL ANALYSIS;

CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; DRUG INDUSTRY; EDITORIAL POLICIES; ENDPOINT DETERMINATION; HUMANS; HYPOGLYCEMIC AGENTS; META-ANALYSIS AS TOPIC; PEER REVIEW, RESEARCH; PHYSICIAN'S ROLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 77949907956     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.337     Document Type: Editorial

References (16)

1. Nissen SE. Setting the RECORD straight. JAMA. 2010;303(12):1194- 1195.
2. Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia. Prepared by the staff of the Committee on Finance, United States Senate, Max Baucus, Chairman, Chuck Grassley, Ranking Member. http://finance.senate.gov/press/ Gpress/2010/prg022010a.pdf. Accessed March 3, 2010.
3. Fontanarosa PB, Flanagin A, DeAngelis CD. Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA. 2005; 294(1):110-111.
4. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry. JAMA. 2008;299(15):1833-1835.
5. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299(15):1800-1812.
6. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008;299(15):1813-1817.
7. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. N Engl J Med. 2005;353(26):2813-2814.
8. Harris GA. Face-off on the safety of a drug for diabetes. New York Times. http: //www.nytimes.com/2010/02/23/health/23niss.html. February 22, 2010. Accessed March 3, 2010.
9. Harris G. Research ties diabetes drug to heart woes. New York Times. February 20, 2010.
10. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med. 2007;357(1):28-38.
11. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.
12. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
13. JAMA instructions for authors. http://www.jama.com/instructions. Updated March 5, 2010.
14. DeAngelis CD, Fontanarosa PB, Flanagin A. Reporting financial conflicts of interest and relationships between investigators and research sponsors. JAMA. 2001; 286(1):89-91.
15. DeAngelis CD, Drazen JM, Frizelle FA, et al; International Committee of Medical Journal Editors. Is this clinical trial fully registered? a statement from the International Committee of Medical Journal Editors. JAMA. 2005;293(23):2927-2929.
16. Zarin DA, Tse T. Medicine: moving towards transparency of clinical trials. Science. 2008;319(5868):1340-1342.